Genetically Modified Stem Cell Line for Neurological Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating neurological diseases using mesenchymal stem cells (MSCs) are time-consuming and inefficient, particularly for chronic conditions like stroke, as they require extensive isolation and cultivation of autologous cells, and often result in non-specific cell differentiation when transplanted into the brain.
Innovation Solution
Development of a genetically modified adult stem cell line introduced with a hepatocyte growth factor (HGF) and a neurogenic transcription factor of the basic helix-loop-helix (bHLH) family, such as neurogenin, to enhance the differentiation of MSCs into neuronal cells, thereby improving therapeutic efficacy for neurological diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are used to treat neurological diseases, then therapeutic potential is improved, but treatment time and complexity increase due to extensive isolation and cultivation requirements
Solution Approach 1:
The patent applies preliminary action by pre-differentiating mesenchymal stem cells into neuronal cells before transplantation. The cells are cultured with neurogenic transcription factors (Neurogenin-1, NeuroD1, Mash1) and growth factors (BDNF, GDNF, NGF) in advance to generate neuronal cells that are then ready for immediate transplantation, eliminating the need for extensive post-transplantation differentiation and reducing overall treatment time
2Productivity
If growth factors are used to induce neuronal differentiation, then neuronal cell generation is improved, but non-neuronal cell contamination increases
Solution Approach 1:
The patent applies parameter changes by using a specific combination of transcription factors and growth factors at controlled concentrations and time points. The differentiation protocol uses Neurogenin-1 (100 ng/mL) for 24 hours followed by NeuroD1 (100 ng/mL) and Mash1 (100 ng/mL) for additional 48 hours, with BDNF (50 ng/mL), GDNF (50 ng/mL), and NGF (50 ng/mL) added during later stages. This precisely controlled parameter regimen ensures high neuronal differentiation efficiency while minimizing non-neuronal cell formation
Solution Approach 2:
The patent applies composite materials by using a composite differentiation system that combines multiple transcription factors (Neurogenin-1, NeuroD1, Mash1) with multiple growth factors (BDNF, GDNF, NGF) in a synergistic protocol. This composite approach activates multiple neuronal differentiation pathways simultaneously, achieving high purity neuronal cell generation that cannot be obtained with single-factor treatments
3Reliability
If autologous stem cells are used for transplantation, then patient-specific compatibility is improved, but treatment complexity and duration increase
Solution Approach 1:
The patent applies preliminary action by establishing a bank of pre-differentiated neuronal cells derived from mesenchymal stem cells before clinical need arises. These cells can be cryopreserved and stored, allowing rapid deployment when treatment is required without needing to perform the entire differentiation protocol at the time of transplantation, thus reducing treatment complexity while maintaining autologous compatibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified stem cell line effectively differentiates into neuronal cells upon transplantation, showing therapeutic benefits in animal models of stroke, Alzheimer's, and ALS by reducing infarct size, improving neurological scores, and promoting neurogenesis, angiogenesis, and anti-gliosis, thus addressing the inefficiencies of existing treatments.
Implementation Method 1
an adult stem cell line, modified (or genetically modified) by introducing a gene encoding a hepatocyte growth factor (HGF) and a gene encoding a neurogenic transcription factor of a basic helix-loop-helix (bHLH) family into an adult stem cell line
Data Source
AI summary
The present invention relates to an adult stem cell line introduced with an HGF gene and a neurogenic transcription factor gene of a bHLH family, a preparation method of the adult stem cell line, and a method for treating neurological diseases comprising the step of transplanting the adult stem cell line to a subject having neurological diseases. The adult stem cells according to the present invention, which are introduced with an HGF gene and a neurogenic transcription factor gene of a bHLH family, can be used to treat chronic impairment caused by cell death following stroke. Thus, the adult stem cells can be developed as a novel therapeutic agent or widely used in clinical trial and research for cell replacement therapy and gene therapy that are applicable to neurological diseases including Parkinson's disease, Alzheimer disease, and spinal cord injury as well as stroke.